Wood­ford's em­bat­tled in­vestors en­dure an­oth­er blow as £550M deal to sell-off biotech hold­ings fal­ters

Neil Wood­ford’s flag­ship fund is in the process of liq­ui­da­tion — and of­fload­ing the now shunned vet­er­an stock pick­er’s non-liq­uid hold­ings is prov­ing a bru­tal task …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER